Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026: prohibited at all times (S0). [1]
2026 List, S0, printed page 4 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Identity and evidence boundary
BPC-157 is a synthetic 15-amino-acid peptide. FDA evaluates its free-base and acetate forms separately. Proposed repair mechanisms and animal experiments do not establish a useful treatment in people. [2]
What human research shows
A 2026 systematic review found three eligible studies involving 30 people: knee symptoms, bladder symptoms and intravenous exposure. It judged the evidence very low certainty. That eligibility count is not the total of every human report: FDA also discusses a 53-person ulcerative-colitis conference abstract. [3] [2]
The intravenous pilot enrolled two adults who had previously received BPC-157. It had no comparison group and monitored participants only through day 3. The authors reported no adverse effects or meaningful changes in the measured laboratory tests. This describes two selected people, not general safety, and the study did not test injury healing. The lead author also described prescribing the peptide and founding a peptide-advocacy organization. [4]
- The systematic review was read at abstract depth; the intravenous pilot was checked in full text. Neither constitutes independent clinical signoff.
Health, marketing and regulatory context
FDA identifies unresolved peptide-quality and immune-reaction concerns, including aggregation and impurities, and a lack of formal immunogenicity testing. Small uncontrolled reports cannot rule out uncommon or long-term harms. [2]
OPSS describes BPC-157 being promoted in wellness and recovery products, including products labelled as research chemicals. Marketing is not evidence of composition or benefit. [5]
The October 2026 HHS policy describes conditional enforcement discretion for specified BPC-157 acetate compounding. It is interim, nonbinding and not FDA approval. It does not establish product safety or permission in sport. [6] [7]
What remains uncertain
- No comprehensive appraisal of every historical human report or ongoing trial was completed.
- The policy is US-specific and conditional; no worldwide legality conclusion is offered.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Effective date; S0 printed page 4; S2 printed pages 7–8
- FDA staff review: BPC-157 related bulk substances, 11 May 2026 ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Identity; human effectiveness evidence; safety/immunogenicity discussion
- Poolton et al. 2026: BPC-157 human evidence systematic review ↗Accessed 2026-11-10 · abstract_only
PubMed abstract; DOI 10.52628/92.3.15837
- Lee and Burgess 2025: intravenous BPC-157 safety pilot ↗Accessed 2026-11-10 · full_text_relevant_sections
Alternative Therapies in Health and Medicine 31(5):20–24; methods, results and disclosure
- OPSS: BPC-157 in health and wellness products ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Marketing/product discussion; page dated 29 April 2025
- Federal Register: HHS peptide compounding policy notice, 30 October 2026 ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Notice and legal effect of policy
- HHS 503A peptide enforcement-discretion policy and Appendix B ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Policy conditions pages 1–4; BPC-157 acetate and TB-500 acetate entries pages 5–7
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.